Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Merck, Schering Deal Could Face Problem with J & J

By Pharmaceutical Processing | March 10, 2009

NEW YORK (AP) — Merck & Co.’s $41.1 billion buyout of Schering-Plough Corp. could face a bump in the road to closing over an international rights dispute to the drug Remicade, several analysts said Tuesday. Kenilworth, N.J.-based Schering-Plough has international marketing rights to the inflammatory condition treatment, which is made by Johnson & Johnson. But, the company loses those rights if it changes control, such as in a buyout. But, the buyout deal has been structured as a “reverse merger” where Schering-Plough will remain as the surviving company, though it will be renamed Merck. “With Schering-Plough and Merck stating that they believe the merger will not impact these marketing rights, we believe that J&J is likely to make the next move via a potential lawsuit (against the companies) to claim the international rights, or by negotiating a payment to reacquire them,” said Caris and Co. analyst David Moskowitz, in a note to investors. He said the buyout could be thrown into upheaval if New Brunswick, N.J.-based J&J ends up with full rights to Remicade, which would in turn lower the value of Schering-Plough. The latter’s investors would be unlikely to accept the $23-per-share bid and Whitehouse Station, N.J.-based Merck’s investors would be unlikely to pay that much, he said. Still, he said the problem will likely be solved through a deal that gives J&J international rights to Remicade for a fair price, while Schering-Plough gets additional cash. Meanwhile, Leerink Swann analyst Seamus Fernandez also expects some action from J&J, but that all the parties involved will work out a fair deal.

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards